Fauci says FDA data shows J&J vaccine should have been two injections – .

Fauci says FDA data shows J&J vaccine should have been two injections – .

President BidenJoe Biden Pressure grows for a breakthrough in Biden agenda talks The state school board is quitting the national association saying they have called out the parents of national terrorists. uncertain whether the United States can maintain the nationwide downward trend in COVID-19 PLUS casesthe chief medical officer of, Antoine FauciAnthony FauciSunday Shows Sneak Peek: Supply Chain Crisis Threatens Holiday Sales; uncertainty over whether US can continue nationwide downtrend in COVID-19 cases CDC Title 42 order fuels racism and undermines public health Advocates step up pressure on Biden to end controversial 42 PLUS title, said on Sunday that the Johnson & Johnson COVID-19 vaccine likely should have been a two-dose injection instead of a single inoculation.
ABC’s Martha Raddatz asked Fauci on “This Week” whether the millions of Americans who have received the Johnson & Johnson (J&J) COVID-19 vaccine should be affected after a Food and Drug Administration advisory committee ( FDA) unanimously voted to recommend that adults receive a shot booster.

– No, not at all, Marthe. I think they should feel good because what the FDA advisers felt is that, given the data they saw, it most likely should have been a two-dose vaccine to begin with ” , Fauci said.

“So the idea of ​​making a recommendation that people who initially received J&J should be given a second dose by age 18 or older without any restrictions on whether or not you are at high risk or not, is that everyone who has received this first dose of J&J who is 18 years of age and over should receive it, ”he added.

Last week, an FDA advisory committee met to vote on whether to recommend Americans receive a Johnson & Johnson vaccine booster. The FDA, which had to rely on data provided by the vaccine manufacturer since trial data had not been provided to the agency on time, decided to vote on its recommendation despite the size of the l sample of 17 people.

The FDA is expected to make a decision soon on the advisory committee’s recommendation. If approved, it would allow adults who received the vaccine to be boosted as early as two months after their initial dose.

The recommendation is unique in that it does not provide the same constraints on who is authorized to receive the recall as the recommendations for Pfizer and Moderna. An FDA panel voted last week to recommend booster shots for people who received both doses of the Moderna vaccine to several groups: those whose use poses a serious risk of COVID-19, people over the age of 65 years old and people who are at higher risk of severe COVID-19 and are between 18 and 64 years old.

People in those categories who received both doses of the Pfizer vaccine were allowed a booster last month.


Please enter your comment!
Please enter your name here